Iptacopan Complement Factor B IgAN — ESENeph MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Complement factor B inhibitor (alternative pathway)
Iptacopan is a selective oral complement factor B inhibitor that blocks the alternative complement pathway. It was approved for IgA nephropathy based on the APPLAUSE-IgAN trial. By inhibiting factor B, it prevents formation of the alternative pathway C3 convertase, reducing complement-mediated glomerular injury. This represents a novel disease-modifying approach targeting the immunological mechanism of IgAN. KDIGO 2025 IgAN guideline references this and other complement-targeting therapies.
Reference: KDIGO 2025 – IgAN Guideline; APPLAUSE-IgAN Trial